Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy

Rajesh K. Kasam(Cincinnati Children's Hospital Medical Center), Satish K. Madala(Cincinnati Children's Hospital Medical Center)
Frontiers in Pharmacology
May 17, 2019
Cited by 33


Related Papers